TLDR
- Cathie Wood’s ARK Invest liquidated 176,093 Iridium Communications shares valued at $3.32 million on December 10, 2025
- ARK acquired 11,342 Nurix Therapeutics shares worth $221,736 after the biotech firm released positive clinical data
- Wood sold 35,379 Adaptive Biotechnologies shares for $525,731 and exited 4,166 Teradyne shares worth $833,075
- ARK reduced Ibotta exposure by 11,700 shares totaling $266,292 in combined transactions
- Trading activity reveals strategic pivot from satellite and tech companies toward biotech sector opportunities
Cathie Wood’s ARK Invest completed several portfolio adjustments on December 10, 2025. The transactions involved multiple exchange-traded funds managed by Wood’s investment firm.
ARK sold its largest position in Iridium Communications during Wednesday’s session. The fund disposed of 176,093 shares across three separate ETFs. These sales occurred through ARK Innovation ETF, ARK Autonomous Technology & Robotics ETF, and ARK Space Exploration & Innovation ETF.
The combined Iridium sale reached $3.32 million in total value. Iridium’s stock had gained 6.3% before ARK executed the transactions. This marks another day of selling after ARK reduced its Iridium stake throughout the previous week.
Iridium Communications Inc., IRDM
ARK simultaneously cut its Teradyne position. The robotics-focused ETF sold 4,166 shares of the semiconductor testing company. This transaction generated proceeds of $833,075.
Genomics Fund Reduces Biotech Position
The ARK Genomic Revolution ETF sold 35,379 shares of Adaptive Biotechnologies. The company specializes in diagnostic tools and immune system research. Adaptive stock rose 5.9% before the sale, which totaled $525,731.
Wood also decreased exposure to Ibotta. ARK sold 11,700 shares of the mobile rewards platform across multiple funds. The Ibotta sales generated $266,292 in combined proceeds.
ARK Adds Cancer Treatment Developer
ARK made a single purchase on December 10. The firm bought 11,342 shares of Nurix Therapeutics through its genomics ETF. The transaction cost $221,736.
Nurix Therapeutics unveiled Phase 1 study results days before ARK’s purchase. The company shared data on bexobrutideg at the American Society of Hematology Annual Meeting. This experimental drug targets Bruton’s tyrosine kinase in blood cancer patients.
The clinical results showed promise for treating hematological cancers. Nurix is developing the drug as a potential therapy for specific blood cancer types. The timing suggests ARK responded to the clinical data release.
Wood has maintained a pattern of gradual position changes. ARK sold Iridium shares on multiple consecutive days rather than exiting completely. The same approach applies to Adaptive Biotechnologies and Ibotta holdings.
The December 10 trades touched five different ARK funds. Each ETF targets specific sectors including innovation, autonomous technology, space, and genomics. The funds operate with distinct investment mandates and stock selections.
ARK’s selling activity centered on communications and technology sectors. The buying focused exclusively on biotech. This pattern indicates Wood is rotating capital from established tech companies into healthcare innovation.
The Iridium divestment represents ARK’s most substantial single-day reduction. Wood has been trimming the satellite communications position to free up capital. The funds are reallocating resources toward companies with different growth profiles.
ARK manages billions in assets across its suite of ETFs. Each fund publishes daily trade reports showing exact share counts and values. Investors track these disclosures to understand Wood’s current investment thesis and sector preferences.
The Wednesday trades show Wood maintaining biotech exposure while reducing satellite and industrial technology positions. ARK continues holding other space-related stocks despite the Iridium sales. The fund’s space ETF contains multiple satellite and aerospace companies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
